News & Updates

Show Multimedia Only

Eribulin, trabectedin active against pleomorphic liposarcoma

07 Apr 2023 by

Eribulin and trabectedin show significant antitumour activity in advanced pleomorphic liposarcoma as compared with conventional chemotherapy, according to retrospective data from the Gustave Roussy cancer centre presented at ESMO SARCOMA 2023.

07 Apr 2023

SLN status optimizes adjuvant therapy decision-making in clinical stage IIB/C melanoma

07 Apr 2023

The performance of a prognostic model with sentinel lymph node (SLN) biopsy status in assessing patient risk for 5-year melanoma-specific death is superior to that of a model with primary tumour staging factors alone for threshold mortality rates ≥30 percent, a study has shown.

07 Apr 2023

Second-line bevacizumab plus irinotecan extends survival in glioblastoma

05 Apr 2023 by

The combination of bevacizumab and irinotecan (BEV+IRI) as second-line treatment of glioblastoma (GBM) results in better median progression-free (PFS) and overall survival (OS) when compared with historical controls, and its toxicity profile is comparable to published data, reports a study.

05 Apr 2023

Watch-and-wait approach for rectal cancer may boost potential of maintaining good quality of life

03 Apr 2023

Patients with rectal cancer who are monitored using a watch-and-wait approach are more likely to have a good quality of life, whereas those who undergo surgery appear to experience deterioration in quality of life and functional outcome, as reported in a study.

03 Apr 2023

Antibiotics linked to higher EAC risk

31 Mar 2023

Exposure to any antibiotics appears to contribute to an increase in the risk of esophageal adenocarcinoma (EAC), with the risk rising as the cumulative days of exposure increases, according to a study.

31 Mar 2023

Original New Drug Application Approvals by US FDA (16-31 March 2023)

31 Mar 2023

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

31 Mar 2023

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.

30 Mar 2023